Beije, N, Abida, W, Antonarakis, ES, Castro, E, de Wit, R, Fizazi, K, Gillessen, S, Hussain, M, Mateo, J, Morris, MJ, Olmos, D, Sartor, O, Sharp, A, Sweeney, CJ, de Bono, JS (2023).
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
EUROPEAN UROLOGY. Editorial Material. 84(3):253-256.
[doi:10.1016/j.eururo.2023.03.038]
Esteban-Villarrubia, J, Ferreiro, CR, Carril-Ajuria, L, Carretero-González, A, Iacovelli, R, Albiges, L, Castellano, D, de Velasco, G (2023).
Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. Article. 41(9).
[doi:10.1016/j.urolonc.2023.05.002]
Chi, KN, Sandhu, S, Smith, MR, Attard, G, Saad, M, Olmos, D, Castro, E, Roubaud, G, Gomes, AJPD, Small, EJ, Rathkopf, DE, Gurney, H, Jung, W, Mason, GE, Dibaj, S, Wu, D, Diorio, B, Urtishak, K, del Corral, A, Francis, P, Kim, W, Efstathiou, E (2023).
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
ANNALS OF ONCOLOGY. Article. 34(9):772-782.
[doi:10.1016/j.annonc.2023.06.009]
Smith, MR, Sandhu, S, George, DJ, Chi, KN, Saad, F, Thiery-Vuillemin, A, Stáhl, O, Olmos, D, Danila, DC, Gafanov, R, Castro, E, Moon, H, Joshua, AM, Mason, GE, Espina, BM, Liu, Y, Lopez-Gitlitz, A, Francis, P, Bevans, KB, Fizazi, K (2023).
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
Journal of Managed Care & Specialty Pharmacy. Article. 29(7):758-768.
Chi, KN, Rathkopf, D, Smith, MR, Efstathiou, E, Attard, G, Olmos, D, Lee, JY, Small, EJ, Pereira de Santana Gomes AJ, Roubaud, G, Saad, M, Zurawski, B, Sakalo, V, Mason, GE, Francis, P, Wang G, Wu, D, Diorio, B, Lopez-Gitlitz, A, Sandhu, S (2023).
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
JOURNAL OF CLINICAL ONCOLOGY. Article. 41(18):3339.
[doi:10.1200/JCO.22.01649]
Matsubara, N, de Bono, J, Sweeney, C, Chi, KN, Olmos, D, Sandhu, S, Massard, C, Garcia, J, Chen, G, Harris, A, Schenkel, F, Sane, R, Hinton, H, Bracarda, S, Sternberg, CN (2023).
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer
CLINICAL GENITOURINARY CANCER. Article. 21(2):230.
[doi:10.1016/j.clgc.2023.01.001]
Esteban-Villarrubia, J, Torres-Jiménez, J, Bueno-Bravo, C, García-Mondaray, R, Subiela, JD, Gajate, P (2023).
Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer
Cancers. Review. 15(3).
[doi:10.3390/cancers15030566]
Chi, KN, Barnicle, A, Sibilla, C, Lai, ZW, Corcoran, C, Barrett, JC, Adelman, CA, Qiu, P, Easter, A, Dearden, S, Oxnard, GR, Agarwal, N, Azad, A, de Bono, J, Mateo, J, Olmos, D, Thiery-Vuillemin, A, Harrington, EA (2023).
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
CLINICAL CANCER RESEARCH. Article. 29(1):81-91.
[doi:10.1158/1078-0432.CCR-22-0931]
